Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RK-4 Injection for Acute Large Hemispheric Infarction
NCT07203521Phase 2Not yet recruiting
- Sponsor
- NeuroDawn
- Start
- Nov 2025
- Primary completion
- Apr 2026
01
Overview
Phase 2, randomised, single-blind trial in brain infarction (2 arms), sponsored by NeuroDawn. Primary endpoint: Proportion of patients achieving mRS scores of 0-3 at Day 90. Planned start Nov 2025; status: not yet recruiting.
02
Conditions
brain infarction
Beyond the preview
Go deeper on NCT07203521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203521.